PROM1 and hepatocellular carcinoma: 5‐FU treatment of the mice injected with PBS‐primed HCC cells resulted in an enrichment of CD133 expressing cells (Figure 4B), which is consistent with our previous findings showing the CD133+ liver CSCs conferred chemoresistance.[20, 21] Our results revealed that rTHBS2 sensitized and enhanced the efficacy of the 5‐FU treatment and reduced CD133 expression, which we now know represents the root of the disease.